Aclarion strengthens balance sheet, extends cash runway into 2028

Aclarion (ACON) announced the closing of a $10.4M common-stock-only financing at $5.18 per share in a clean capital raise structure. The transaction materially strengthens Aclarion’s balance sheet, preserves capital structure integrity, and significantly extends the company’s operating runway well past targeted near and medium-term catalysts while enhancing strategic flexibility as Nociscan continues to gain clinical and commercial traction. The company believes its strengthened capital position fully supports continued execution across commercialization, evidence generation, and strategic partnerships in the lead up toward additional payor coverage. The company has $21.6M in cash as of January 12 and zero debt. Its cash runway is extended into 2028 based on current operating plans.